Tackling Antibiotic Resistance - ENABLE Project
An Oxford impact case study has highlighted the work by Jürgen Brem and colleagues in the Department of Chemistry are collaborating with academic and industry partners to develop therapies tackling antibiotic resistance.
The project is supported by the European Innovative Medicines Initiative funded ENABLE (European Gram-Negative Antibacterial Engine) programme, which includes universities, pharmaceutical companies and contract research organisations in Europe, the United States, and elsewhere.
Project Leader, Jürgen Brem, explains the importance of the collaboration. "Getting a new drug or therapy from 'bench to clinic' is normally a slow process. The ENABLE network is a collaboration of extremely committed and experienced people, with a real passion for antibiotic research. Being able to draw on the network, and the rapid development of new knowledge by partners with specialist expertise, have been crucial in getting the new drug candidate to this stage."
A key goal of the project will be creating a therapy which will also be useful to developing countries. "Producing something for countries in the Global South is part of our vision," explains Brem. "Places such as India, Pakistan, Brazil and China are particularly affected by antibiotic resistance but cannot afford expensive new drugs. Making a drug that is losing its effectiveness work again makes a lot of sense in this context."